m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05116
 [1]
Non-coding RNA HCP5 YTHDF1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification HK2 HK2 YTHDF1 : m6A sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 1 (YTHDF1) READER
 Regulator Info 
m6A Target Hexokinase-2 (HK2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator HLA complex P5 (HCP5) LncRNA View Details
Regulated Target YTH domain-containing family protein 1 (YTHDF1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary HCP5 was able to directly interact with YTHDF1, a N6-methyladenosine (m6A) reader, enhancing the binding of YTHDF1 to m6A-modified Hexokinase-2 (HK2) mRNA, leading to increasing HK2 stability, thereby promoting the Warburg effect (aerobic glycolysis) of ESCC cells
Responsed Disease Esophageal Squamous Cell Carcinoma ICD-11: 2B70.1
 Disease Info 
In-vitro Model
 HET-1A Normal Homo sapiens CVCL_3702
Eca-109 Esophageal squamous cell carcinoma Homo sapiens CVCL_6898
TE-10 Esophageal squamous cell carcinoma Homo sapiens CVCL_1760
In-vivo Model Six-week-old male nude BALB/C mice were randomly divided into two groups, NC and sh-HCP5#1 groups. 2 × 106 EC109 cells were subcutaneously injected into nude mice and grown for 5 weeks.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Hexokinase-2 (HK2) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name VDA-1102 Phase 2 [2]
MOA Modulator
External Link
TTD: D06QBX
2B70: Esophageal cancer 15 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Pembrolizumab Approved [3]
External Link
TTD: D08ANZ
 Compound Name Nivolumab Approved [3]
External Link
TTD: D00GOV
 Compound Name Claudiximab Phase 3 [4]
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
    Click to Show/Hide
External Link
TTD: D0B3ZC
 Compound Name Golnerminogene pradenovac Phase 3 [5]
Synonyms
TNFerade (TN)
    Click to Show/Hide
External Link
TTD: D03QBT
 Compound Name DKN-01 Phase 2 [6]
External Link
TTD: DMF73Z
 Compound Name Pegamotecan Phase 2 [7]
Synonyms
Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
    Click to Show/Hide
External Link
CID: 11297617
TTD: D0D4CX
 Compound Name APR-246 Phase 2 [3]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name Opdivo + Yervoy Phase 3 [3]
External Link
TTD: D02VYE
 Compound Name Anti-NY-ESO-1 CAR-T cells Phase 1/2 [8]
External Link
TTD: D0LJ2S
 Compound Name Anti-MUC1 CAR-T cells Phase 1/2 [9]
External Link
TTD: D09KWN
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [10]
External Link
TTD: D08QYW
 Compound Name PCA062 Phase 1 [3]
External Link
TTD: D09WSR
 Compound Name Cellspan esophageal implant Clinical trial [3]
External Link
TTD: D0SW1D
 Compound Name PKI166 Discontinued in Phase 2 [11]
Synonyms
PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, > 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol
    Click to Show/Hide
External Link
CID: 6918403
TTD: D07GFF
 Compound Name Ramorelix Discontinued in Phase 1 [12]
Synonyms
Hoe-013
    Click to Show/Hide
External Link
CID: 25077455
TTD: D0S6AQ
References
Ref 1 HLA complex P5 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma. Bioengineered. 2022 Apr;13(4):9301-9311. doi: 10.1080/21655979.2022.2051854.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 ClinicalTrials.gov (NCT01197885) Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer. U.S. National Institutes of Health.
Ref 5 ClinicalTrials.gov (NCT00051467) A Study of TNFerade Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 ClinicalTrials.gov (NCT00080002) Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
Ref 8 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 9 ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
Ref 10 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7642).
Ref 12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008630)